首页> 美国卫生研究院文献>International Journal of Molecular Sciences >DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia
【2h】

DA-9701 (Motilitone): A Multi-Targeting Botanical Drug for the Treatment of Functional Dyspepsia

机译:DA-9701(Motilitone):一种用于治疗功能性消化不良的多靶点植物药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Functional dyspepsia (FD) is the most common functional gastrointestinal disorder (FGID). FD is characterized by bothersome symptoms such as postprandial fullness, early satiety, and epigastric pain or burning sensations in the upper abdomen. The complexity and heterogeneity of FD pathophysiology, which involves multiple mechanisms, make both treatment and new drug development for FD difficult. Current medicines for FD targeting a single pathway have failed to show satisfactory efficacy and safety. On the other hand, multicomponent herbal medicines that act on multiple targets may be a promising alternative treatment for FD. DA-9701 (Motilitone), a botanical drug consisting of Corydalis Tuber and Pharbitidis Semen, has been prescribed for FD since it was launched in Korea in 2011. It has multiple mechanisms of action such as prokinetic effects, fundus relaxation, and visceral analgesia, which are mediated by dopamine D2 and several serotonin receptors involved in gastrointestinal (GI) functions. In clinical studies, DA-9701 has been found to be beneficial for improvement of FD symptoms and GI functions in FD patients, while showing better safety compared to that associated with conventional medicines. In this review, we provide updated information on the pharmacological effects, safety, and clinical results of DA-9701 for the treatment of FGIDs.
机译:功能性消化不良(FD)是最常见的功能性胃肠疾病(FGID)。 FD的特征是令人讨厌的症状,例如餐后饱胀,饱腹感和上腹痛或上腹部灼热感。 FD病理生理学的复杂性和异质性涉及多种机制,使得FD的治疗和新药开发都变得困难。目前针对单一途径的FD药物未能显示出令人满意的疗效和安全性。另一方面,作用于多个目标的多成分草药可能是FD的有前途的替代疗法。自2011年在韩国投放市场以来,DA-9701(Motilitone)是由延胡索块茎和法比第氏精液组成的植物药,已被指定用于FD。它具有多种作用机制,例如促动力学作用,眼底松弛和内脏镇痛,它们是由多巴胺D2和参与胃肠功能的几种血清素受体介导的。在临床研究中,已发现DA-9701对改善FD患者的FD症状和GI功能有益,同时与传统药物相比,显示出更好的安全性。在这篇综述中,我们提供了有关DA-9701用于治疗FGIDs的药理作用,安全性和临床结果的最新信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号